Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-speciWc immune responses and antitumor eVects

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 1941-1951

  Osada, Takuya ^a   Berglund, Peter ^b   Morse, Michael A ^a,c   Hubby, Bolyn ^b   Lewis, Whitney ^d   Niedzwiecki, Donna ^c   Yang, Xiao Yi ^a   Hobeika, Amy ^a   Burnett, Bruce ^c   Devi, Gayathri R ^a,c   Clay, Timothy M ^a,c   Smith, Jonathan ^b   Lyerly, H Kim ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Liquidia Technologies   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d PRECISION BIOSCIENCES   (United States)

Author keywords

Alphavirus; Cancer vaccine; CEA; Interleukin 12

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG; VENEZUELAN EQUINE ENCEPHALITIS VIRUS REPLICON PARTICLE VECTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER SIZE; CANCER SURVIVAL; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; HUMANS; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; REPLICON; T-LYMPHOCYTES; VIRION;

EID: 84871004190     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1248-y     Document Type: Article

References (35)

1. Yang S, Kittlesen D, SlingluV CL, Vervaert CE, Seigler HF, Darrow TL (2000) Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple speciWcities and elicit high aYnity T cells reactive to multipleepitopes and restricted by HLA-A2 and -A3. J. Immunol 164:4204-4211
2. zum Büschenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H (2001) The generation of both T killer and Th cell clones speciWc for the tumor-Associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol 167:1712-1719
3. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature 413:732-738
4. Diebold SS, Montoya M, Unger H, Alexopoulou L, Roy P, Haswell LE et al (2003) Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424:324-328
5. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401
6. Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA et al (1997) Humoral, mucosal, and cellular immunity in response to a human immunodeWciency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 71:3031-3038
7. MacDonald GH, Johnston RE (2000) Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 74:914-922
8. Moran TP, Collier M, McKinnon KP, Davis NL, Johnston RE, Serody JS (2005) A novel viral system for generating antigen-speciWc T cells. J Immunol 175:3431-3438
9. Gardner JP, Frolov I, Perri S, Ji Y, MacKichan ML, zur Megede J et al (2000) Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol 74:11849-11857
10. Mazzoni A, Segal DM (2004) Controlling the Toll road to dendritic cell polarization. J Leukoc Biol 75:721-730
11. Morse MA, Hobeika A, Osada T, Berglund P, Negri S, Niedzwiecki D et al (2010) A novel recombinant alphaviral vector breaks tolerance to self-Antigen in the setting of elevated regulatory T cells. J Clin Invest 120:3234-3241
12. DranoV G, JaVee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, speciWc, and long-lasting anti-Tumor immunity. Proc Natl Acad Sci USA 90:3539-3543
13. Trinchieri G (1998) ProinXammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16:365-396
14. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J (1991) Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51:3657-3662
15. Talarico T, Maughan M, Pancorbo B, Ruiz J, Graham A (2006) Development and manufacture of alphavaccines. Bioprocessing Fall:8-14
16. Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI et al (2007) Development and preclinical evaluation of an alphavirus replicon vaccine for inXuenza. Vaccine 25:8180-8189
17. Mosca PJ, Hobeika AC, Clay TM, Nair SK, Thomas EK, Morse MA et al (2000) A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 96:3499-350418. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146
18. Robertson MJ, SoiVer RJ, Wolf SF, Manley TJ, Donahue C, Young D et al (1992) Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are diVerentially regulated by NKSF. J Exp Med 175:779-788
19. Grufman P, Kärre K (2000) Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol 30:1088-1093
20. Gherardi MM, Ramírez JC, Esteban M (2001) Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol Histopathol 16:655-667
21. Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT et al (2006) Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 107:4650-4657
22. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME et al (2002) Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8:3686-3695
23. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F et al (2004) Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10:5432-5438
24. Robertson MJ, Pelloso D, Abonour R, Hromas RA, Nelson RP Jr, Wood L et al (2002) Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin Cancer Res 8:3383-3393
25. Peeva E, Fishman AD, Goddard G, Wadler S, Barland P (2000) Rheumatoid arthritis exacerbation caused by exogenous interleukin-12. Arthritis Rheum 43:461-463
26. Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E et al (2004) A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol 92:957-964
27. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG et al (2002) Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99:67-74
28. Parihar R, Nadella P, Lewis A, Jensen R, De HoV C, Dierksheide JE et al (2004) A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 10:5027-5037
29. Eisenbeis CF, Lesinski GB, Anghelina M, Parihar R, Valentino D, Liu J et al (2005) Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 23:8835-8844
30. Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T et al (2004) Clinical and immunologic eVects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22:2891-2900
31. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al (1999) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690-1695
32. Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W et al (2007) Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 13:215-222
33. Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21:2342-2348.
34. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB et al (1997) EVects of single-dose interleukin-12 exposure on interleukin-12- Associated toxicity and interferon-gamma production. Blood 90:2541-2548
35. Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R et al (1999) Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-Term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clin Pharmacol Ther 65:615-629